Reducing MACE in a Patient With T2DM and ASCVD

Description

This activity is part of the Clinical Spotlight Series: Tracking the CV Impact of SGLT2i: Practice Essentials.

Accreditation Statement
In accordance with ACCME policy, prior to participating in this activity, you must review the information on this page.

Joint Accreditation

In support of improving patient care, the American College of Cardiology Foundation (ACCF) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement
Physicians

The ACCF designates this online enduring material for a maximum of up to .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

While offering the CME credits noted above, this program is not intended to provide extensive training or certification in the field.

MOC Information

Successful completion of this certified activity, which includes participation in the evaluation component, enables the participant to earn up to .25 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses
The ACCF designates this educational activity for a maximum of .25 continuing nursing education contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity.

Learner Objectives

Upon completion of this activity, you should be able to:

Apply practical approaches for utilizing SGLT2 inhibitors in clinical practice, including initiation, dosing, dose modifications, contraindications, cautions, and adverse effects.

Target Audience

This activity is intended for CV team clinicians including physicians, nurse practitioners, physician assistants, and pharmacists who manage patients with or at risk for ASCVD and/or heart failure. 

Important Dates
Date of Release: September 1, 2021
Term of Approval/Date of Expiration: September 1, 2022

Acknowledgement
This activity is supported by an unrestricted educational grant from AstraZeneca and Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Faculty
Alison Bailey, MD, FACC

Peer Reviewers
Michelle Kittleson, MD, FACC
James L. Januzzi, Jr., MD, FACC

Summary


Availability:	Retired


Cost:	FREE


Credit Offered:	No Credit Offered